Moreover, in CCL-138 and CCL-138-R cells, treatment with dasatinib (a major p-Src inhibitor) led to a reduction in the CD44 and Sox2 protein levels (Figure S9A) without affecting the SDCBP expression levels (data not shown), and it sensitized HNSCC cells to CDDP (Figure S9B). The gene discussed is SRC; the disease is head and neck squamous cell carcinoma.